Treatment protocols for small cell lung cancer (SCLC) are provided below, including the following: First-line therapy Therapy for limited-stage disease Therapy for extensive-stage disease Treatment recommendations for limited-stage SCLC Stages I-III disease: Limited-stage disease is typically treate...
In contrast to non-small cell lung cancer (NSCLC), SCLC is staged as either limited-stage disease (LD) or extensive-stage disease (ED). Chemotherapy remains the essential component for treatment of all patients with SCLC, regardless of stage or performance status. In LD, the addition of ...
Small-cell lung cancer is an aggressive tumor associated with highrates of regional or distant metastases at diagnosis. Although highlychemosensitive to agents given in the first-line setting (eg, etoposideand cisplatin), most patients relapse and have a poor prognosis.Treatment options for relapsed ...
For more than three decades, care for small-celllung cancer(SCLC) remained mostly the same. That’s changing now -- doctors have a new option called immunotherapy. This line of treatment uses your body’s own immune system to fight cancer. What Is Immunotherapy? The immune system is your ...
When CPT-11 is used as a single agent with concurrent radiation therapy, the dose of CPT-11 must be reduced Progress in treatment of small - cell lung cancer N Saijo 2181 from 100 to 60 mg mÀ2 in a weekly schedule. However, this dose reduction may reduce the efficacy of CPT-11 in...
Staging of the cancer provides important information about the outlook of your condition and helps your doctor plan the best treatment. Small-cell lung cancer has two stages: limited and extensive. That makes it different from other cancers, which go from stage I to stage IV. ...
Kartik Konduri, MD, discusses treatment options for extensive-stage small cell lung cancer. EP: 1.Evaluation of a Patient with Small Cell Lung Cancer Now Viewing EP: 2.Treatment Options in Small Cell Lung Cancer EP: 3.Lurbinectedin in the Treatment of Small Cell Lung Cancer EP: 4.The ...
small cell lung cancer; treatment Abstract: Lung cancer was relatively uncommon at the turn of the 20th century, and has increased in prevalence at alarming rates, particularly because of the augmented trend in smoking, so that it is now the most common cause of cancer death in the world. ...
近期,由杨跃教授作为通讯作者,吕超教授、方文涛教授等作为主要作者发起的,探索奥希替尼用于可切除的EGFR阳性NSCLC新辅助治疗的ⅡB期临床研究NEOS重磅发表于《Lung Cancer》杂志,有望填补NSCLC新辅助治疗领域的靶向治疗空白,为更多患者带来精准治疗方案,提高治愈率。
EORTC(European Organization for Research and Treatment of Cancer)的一项研究,将对化疗有反应的患者随机化分为2组,接受PCI或不接受PCI,发现PCI治疗组1年生存率为27.1%,未接受PCI者为13.3%。[49]在该研究中,PCI不仅减少脑转移的发生率也提高无病生存率和总体生存率。然而,欧洲肿瘤医学学会(ESMO)2010年的实践...